KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacira BioSciences (PCRX) Operating Expenses (2016 - 2026)

Pacira BioSciences has reported Operating Expenses over the past 17 years, most recently at $170.5 million for Q1 2026.

  • For Q1 2026, Operating Expenses rose 2.12% year-over-year to $170.5 million; the TTM value through Mar 2026 reached $710.8 million, down 9.73%, while the annual FY2025 figure was $707.2 million, 8.67% down from the prior year.
  • Operating Expenses for Q1 2026 was $170.5 million at Pacira BioSciences, down from $194.5 million in the prior quarter.
  • Over five years, Operating Expenses peaked at $308.1 million in Q3 2024 and troughed at $129.6 million in Q2 2023.
  • A 5-year average of $167.4 million and a median of $162.5 million in 2024 define the central range for Operating Expenses.
  • Biggest five-year swings in Operating Expenses: surged 110.73% in 2024 and later crashed 43.8% in 2025.
  • Year by year, Operating Expenses stood at $181.8 million in 2022, then fell by 18.57% to $148.1 million in 2023, then rose by 9.77% to $162.5 million in 2024, then grew by 19.68% to $194.5 million in 2025, then dropped by 12.37% to $170.5 million in 2026.
  • Business Quant data shows Operating Expenses for PCRX at $170.5 million in Q1 2026, $194.5 million in Q4 2025, and $173.2 million in Q3 2025.